We next assessed SETD2 mRNA levels by RT‐qPCR, but they appeared not to be significantly lower in patients with no or low SETD2 expression as compared with HD (Figure 2S), which led us to exclude the occurrence of gene deletions, haploinsufficiency or promoter hyper‐methylation. Here, SETD2 is linked to Huntington disease.